At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
In Brief
A clinical study evaluating Budesonide 360ug, Budesonide 720ug, and 3 other interventions for Asthma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists).
Study Details
Timeline
Interventions
A single inhaled dose of 360ug budesonide from a DPI.
A single inhaled dose of 720ug budesonide from a DPI.
A single dose of 1440ug of the budesonide from DPI.
720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
A single inhaled dose of placebo from a DPI.